Syringes and Vials: The Foundation of Insulin Therapy
Syringes and vials have been the go-to tools for insulin therapy for a long time, as they provide a straightforward and effective way of delivering insulin to the body. Even though new methods of insulin delivery have been developed, many people with diabetes still depend on syringes and vials for their insulin needs. These tools are widely used by patients all over the world because they are familiar, affordable, and easy to access.
Insulin pens Vs syringes in insulin delivery
An insulin pen is a device that looks like a marker pen. It's used to inject insulin into the fatty tissue via a thin needle. It's preferred by travelers over syringes because it integrates the medication and delivery system, making it more convenient to use. To use an insulin pen, you twist or snap on a new needle, dial the required dose, inject the insulin, and then discard the used needle into a safe container.
Advantages of Insulin Pens:
- Ease of Use: Insulin pens are designed for simplicity, featuring pre-filled cartridges and a dial mechanism to select the desired dose.
- Disposable and Reusable Options: Insulin pens offer flexibility in choice with both disposable and reusable forms, based on individual preferences and environmental considerations.
- Dose Accuracy: Insulin pens offer accurate and precise dose delivery, allowing users to manage their diabetes effectively.
Advantages of Syringes:
- Cost-Effectiveness: Syringes are a cost-effective alternative to insulin pens, particularly for people with large insulin doses or no pen insurance. They're preferred in regions with limited healthcare resources.
- Accessibility: Syringes are easily accessible without a prescription in many areas, ensuring reliable insulin delivery for people with diabetes regardless of their healthcare setting or location.
- Customizable Dosage: Syringes allow for precise dosage adjustment, offering flexibility for individuals with specific insulin requirements or those who need to mix different types of insulin. This customization is particularly beneficial for people with varying insulin sensitivities or insulin resistance.
Leading Players
In the field of diabetes management, there are several leading players who drive innovation in insulin delivery devices. Here are some of the key players:
Novo Nordisk
Novo Nordisk A/S is a multinational pharmaceutical company from Denmark that specializes in producing medications for diabetes care and other healthcare products. The company was founded in 1923 and is headquartered in Bagsværd, Denmark. Novo Nordisk is a global leader in diabetes care and provides a comprehensive range of insulin products, GLP-1 receptor agonists, and other related therapies. In 2023, the company's revenue was $33,709.9 million.
Eli Lilly
Eli Lilly is one of the oldest U.S. pharmaceutical companies. The company was founded in 1876 and is headquartered in Indiana, U.S. The company products are sold in approximately 120 countries. It has manufacturing plants in 13 countries, with R&D facilities in six countries. In 2023, the company's revenue was $ 34,124.1million.
SANOFI
Sanofi is a pharmaceutical company established in 1994 with 3 segments: pharmaceuticals, consumer healthcare, and vaccines. It operates 69 manufacturing sites in 32 countries. In FY2023, Sanofi's revenue increased by 3.1% compared to FY2022. This is due to higher sales of vaccines and Dupixent.
MEDTRONIC
Medtronic is a global leader in diabetes management technology. Founded in 1949, the company is headquartered in Minnesota, U.S. Their insulin pump systems, like the MiniMed series, offer continuous subcutaneous insulin infusion for precise delivery. The integrated insulin pump systems, combined with continuous glucose monitoring, provide advanced tools for personalized diabetes management. In 2023, Medtronic's revenue was $31,227 million.
AstraZeneca
AstraZeneca is a multinational pharmaceutical company that specializes in various therapeutic areas such as cardiovascular, oncology, respiratory, and diabetes care. The company was founded in 1999 and has its headquarters in Cambridge, U.K. It markets its medicines in more than 100 countries and has a diverse portfolio of products. With over 600 collaborations worldwide, the company has expanded its pipeline portfolio. AstraZeneca operates manufacturing facilities in 18 countries and has a considerable presence in emerging markets, particularly China. Additionally, the company markets drugs for treating diabetes, and in 2023, it recorded a revenue of $45,811 million.
Future of Emerging Insulin Drug and Delivery Technologies
According to the report by BCC Research, the global market for emerging insulin drug and delivery technologies was valued at $55.8 billion in 2023. The market is expected to grow steadily at a rate of 9.8% from 2023 to 2028 and reach over $88.9 billion by the end of 2028. This growth is attributed to several factors, including the increasing prevalence of diabetes worldwide, which drives the demand for effective diabetes management solutions. Moreover, advancements in healthcare technology and infrastructure are facilitating the development of innovative insulin delivery devices with improved precision, user-friendliness, and patient comfort, thereby boosting market growth.
Learn More and Take Action:
Consider becoming a member of the BCC Research library and gain access to our full catalog of market research reports in your industry. Not seeing what you are looking for? We offer custom solutions too, including our new product line: Custom Intelligence Services.
Contact us today to find out more.
